Nasdaq-listed Anixa Biosciences board approves purchase of Bitcoin as reserve asset
Golden Finance reported that the board of directors of Nasdaq-listed Anixa Biosciences has approved the purchase of Bitcoin as a reserve asset. The company also reiterated its ongoing stock repurchase plan. The company's CEO Amit Kumar said that the decision on Bitcoin is another way of prudent financial management to achieve higher shareholder value. It is reported that Anixa Biosciences is a biotechnology company focused on the treatment and prevention of cancer.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Data: The tokens with the highest smart money net inflows in the past 24 hours are MAGICIAN, AIPEPE, and CHILLHOUSE
Bio Protocol Enters V2 Phase, Users Can Earn BioXP Through Staking
BAYC#7940 Sold 23 Hours Ago for 666 ETH, Valued at Approximately $2.348 Million
Trending news
MoreCrypto prices
More








